Redefining cancer treatment to one day eliminate cancer as a cause of death.

Our ambition is to push the boundaries of science to change the practice of medicine and transform the lives of patients living with cancer.   

To accomplish this, we focus on research and development and our commercial capabilities to deliver a new generation of medicines that have the potential to redefine cancer treatment.

Our approach to Oncology

We follow four strategic priorities to help us achieve our ambition to eliminate cancer as a cause of death:

Focus research on four scientific platforms

We’re targeting the underlying biological drivers of cancer by focusing on four different scientific platforms: Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response, and Antibody Drug Conjugates.

Utilise precision medicine in the most prevalent and deadly tumour types

We’re concentrating on biomarker-driven indications to dramatically improve five-year survival in five tumour types, including ovarian cancer and non-small cell lung cancer (NSCLC).

Focus on early stages of disease and relapsed patients

Our patient-centric approach focuses on 1) identifying and treating patients earlier in the course of their disease with curative intent; and 2) supporting relapsed and refractory patients by tackling primary or acquired resistance.

Leverage our global footprint

We’re expanding our presence across geographies to deliver timely treatments to patients in the US, UK, Italy, France, Germany, Spain, Japan, and China.

Key disease areas

Among the many different types of cancer that our scientists explore, we are developing new treatment approaches for the following types of cancer:

Our scientific platforms

We’re concentrating on four scientific platforms that we believe show the greatest potential for yielding effective medicines for cancer patients.

  • Immuno-Oncology (IO)

    Activating the body’s own immune system to help fight cancer

  • Tumour Drivers and Resistance (TDR)

    Targeting the genetic mutations and resistance mechanisms that enable cancer cells to evade treatment, survive, and proliferate

  • DNA Damage Response (DDR)

    Targeting the DNA repair process to block cancer cells’ ability to reproduce

  • Antibody Drug Conjugates (ADC)

    Delivering highly potent cancer-killing agents directly to cancer cells via a linker attached to a targeted antibody

Where science brings us

As part of our commitment to Oncology, we’re constantly working on new and exciting workstreams.
Here are just a few of what we’re up to at the moment.


Lung Ambition Alliance

Lung cancer is at the forefront of AstraZeneca’s research and development focus. Our expanding portfolio aims to provide medicines that can improve outcomes at every stage of the disease. But we know if we are to make meaningful progress for lung cancer patients, we cannot work alone. We have partnered with the International Association for the Study of Lung Cancer (IASLC), the Global Lung Cancer Coalition (GLCC), and Guardant Health to form the Lung Ambition Alliance.  Together we are taking urgent action to double five-year survival in lung cancer globally by 2025 – prioritising research and projects that increase screening, deliver innovative medicine and improve quality care.

The great advance of personalised healthcare, in oncology, has been the realisation that some tumours are driven by individual genes. So if you can find out which genes these are, you can develop a medicine that's best for that tumour, and then select patients that are best for that medicine.

Ruth March Senior Vice-President of Precision Medicine, R&D Oncology

Collaboration in Oncology

To eliminate cancer as a cause of death, we understand that we cannot work alone. Improving patient outcomes requires a collaborative approach to research and development.

Our Oncology pipeline

Our robust pipeline includes investigational therapies in varied stages of clinical development, from recently approved products to earlier-stage molecules in clinical trials. We aspire to transform the lives of cancer patients, working to eliminate cancer as a cause of death in the future.


Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III or have been submitted for regulatory approval, and may include assets that are launched in one or more major markets (removed when launched in all applicable major markets).

Oncology (as at 25 July 2019)

Phase I

Phase I

  • AZD1390 glioblastoma
  • AZD4573 haematalogical malignancies
  • AZD5153 solid tumours
  • AZD5991 haematalogical malignancies
  • AZD9496 oestrogen receptor +ve breast cancer
  • AZD9833 oestrogen receptor +ve breast cancer
  • Calquence + AZD6738 haematological malignancies
  • Calquence + danvatirsen haematological malignancies
  • Imfinzi + adavosertib solid tumours
  • Imfinzi + RT (platform) CLOVER locally-advanced head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer
  • Imfinzi + selumetinib solid tumours
  • Imfinzi + tremelimumab solid tumours
  • Imfinzi + tremelimumab + CTx 1st-line pancreatic ductal adenocarcinoma, oesophageal and small cell lung cancer
  • MEDI1191 solid tumours
  • MEDI2228 multiple myeloma
  • MEDI5083 solid tumours
  • MEDI5752 solid tumours
  • MEDI7247 haematological malignancies, solid tumours
  • oleclumab solid tumours
  • oleclumab + AZD4635 EGFRm NSCLC
  • oleclumab + Tagrisso EGFRm NSCLC

Phase II

Phase II

  • (oleclumab+CTx) or (Imfinzi+oleclumab+CTx) metastatic pancreatic cancer
  • adavosertib ovarian cancer, solid tumours
  • AZD2811 solid tumours
  • AZD4635 solid tumours
  • capivasertib breast cancer, prostate cancer
  • Imfinzi + (oleclumab or monalizumab) COAST non small cell lung cancer
  • Imfinzi + (oleclumab or monlizumab or danvatirsen) NeoCOAST non small cell lung cancer
  • Imfinzi + AZD5069 or Imfinzi + danvatirsen head and neck squamous cell carcinoma, bladder and NSCLC
  • Imfinzi + Lynparza BAYOU 1st-line unresectable stage IV bladder cancer
  • Imfinzi + Lynparza ORION 1st-line metastatic non-small cell lung cancer
  • Imfinzi + MEDI0457 head and neck squamous cell carcinoma
  • Imfinzi + monalizumab solid tumours
  • Imfinzi + oleclumab solid tumours
  • Imfinzi + tremelimumab biliary tract, oesophageal
  • Imfinzi + tremelimumab gastric cancer
  • Lynparza + adavosertib solid tumours
  • Lynparza + AZD6738 or Lynparza + adavosertib VIOLETTE breast cancer
  • Lynparza + Imfinzi MEDIOLA ovarian cancer, breast cancer, gastic cancer and small-cell lung cancer
  • Tagrisso + or selumetinib or savolitinib) TATTON advanced EGFRm non-small cell lung cancer
  • Tagrisso + savolitinib SAVANNAH advanced EGFRm non-small cell lung cancer
  • trastuzumab deruxtecan (DS-8201) HER2-expressing advanced colorectal cancer
  • trastuzumab deruxtecan (DS-8201) HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non Small Cell Lung Cancer

Phase III

Phase III

  • capivasertib + CTx CAPItello-290 1st-line metastatic triple negative breast cancer
  • Imfinzi + tremelimumab DANUBE 1st-line bladder cancer
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumab KESTREL 1st-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab NEPTUNE 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab + CRT ADRIATIC LD-SCLC
  • Imfinzi + tremelimumab + CTx POSEIDON 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab + SoC CASPIAN 1st-line small cell lung cancer
  • Imfinzi + tremelimumab + SoC NILE 1st-line urothelial cancer
  • Lumoxiti 3rd-line hairy cell leukaemia
  • Lynparza + Imfinzi + bevacizumab DUO-O 1st-line ovarian cancer
  • savolitinib SAVOIR papillary renal cell carcinoma
  • selumetinib SPRINT paediatric neurofibromatosis type-1
  • trastuzumab deruxtecan (DS-8201) DESTINY-Breast02 HER2-positive, Unresectable and/or Metastatic Breast Cancer Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1
  • trastuzumab deruxtecan (DS-8201) DESTINY-Breast04 HER2-low, unresectable and/or metastatic breast cancer subjects
  • trastuzumab deruxtecan (DS-8201) DESTINY-Breast01 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
  • trastuzumab deruxtecan (DS-8201) DESTINY-Breast03 HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane
  • trastuzumab deruxtecan (DS-8201) DESTINY-Gastric01 HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens

LCM Projects

LCM Projects

  • Calquence ECHO 1st-line mantle cell lymphoma
  • Calquence ASCEND relapsed/refractory chronic lymphocytic leukaemia
  • Calquence ELEVATE-RR relapsed/refractory chronic lymphocytic leukaemia, high risk
  • Calquence ELEVATE-TN 1st-line chronic lymphocytic leukaemia
  • Calquence + venetoclax + obinutuzumab 1st-line chronic lymphocytic leukaemia
  • Imfinzi CALLA locally-advanced cervical cancer
  • Imfinzi POTOMAC non muscle invasive bladder cancer
  • Imfinzi PACIFIC locally advanced (stage III) NSCLC
  • Imfinzi solid tumours
  • Imfinzi PEARL 1st-line non-small cell lung cancer
  • Imfinzi (platform) BEGONIA 1st-line metastatic triple negative breast cancer
  • Imfinzi (platform) MAGELLAN 1st-line metastatic non-small cell lung cancer
  • Imfinzi + azacitidine myelodysplastic syndrome
  • Imfinzi + CRT PACIFIC-2 locally-advanced (stage III) NSCLC
  • Imfinzi + CRT PACIFIC-5 (China) locally-advanced (stage III) NSCLC
  • Imfinzi + CTx NIAGARA muscle invasive bladder cancer
  • Imfinzi + CTx TOPAZ-1 1st-line biliary tract cancer
  • Imfinzi + CTx neoadjuvant AEGEAN locally-advanced (stage III) NSCLC
  • Imfinzi + VEGF EMERALD-2 adjuvant hepatocellar carcinoma
  • Imfinzi + VEGF + TACE EMERALD-1 locoregional hepatocellar carcinoma
  • Imfinzi post-SBRT PACIFIC-4 stage I/II non-small cell lung cancer
  • Lynparza PROfound prostate cancer
  • Lynparza SOLO-1 1st-line BRCAm ovarian cancer
  • Lynparza SOLO-2 2nd-line or greater BRCAm PSR ovarian cancer, maintenance monotherapy
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Lynparza OlympiAD gBRCA metastatic breast cancer
  • Lynparza POLO pancreatic cancer
  • Lynparza SOLO-3 gBRCA PSR ovarian cancer
  • Lynparza (basket) MK-7339-002 / LYNK002 HRRm cancer
  • Lynparza + abiraterone PROpel prostate cancer
  • Lynparza + cediranib CONCERTO recurrent platinum-resistant ovarian cancer
  • Tagrisso ADAURA adjuvant EGFRm non-small cell lung cancer
  • Tagrisso FLAURA 1st-line advanced EGFRm non-small cell lung cancer
  • Tagrisso LAURA stage 3 EGFRm non-small cell lung cancer

Our Oncology medicines

Our Oncology medicines

We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations. Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.





Casodex, Cosudex













goserelin acetate implant

Our Resources


1.   Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6:57. https://doi.org/10.1186/s40425-018-0360-8.

2.     McGowan CH, Russell P. Human Wee 1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J. 1993 Jan; 12(1):75-85.

3.     Tominaga Y, Li C, Wang RH, Deng CX. Murine Wee1 plays a critical role in cell cycle regulation and preimplantation stages of embryonic development. J Biol Sci. 2006; 2(4):161-170.

4.     Guertin AD, Li J, Liu Y, et al. Preclinical evaluation of the Wee-1 inhibitor MK-1775 as a single-agent anticancer therapy. Mol Cancer Ther. 2013 Aug;12(8):1442-1452.

5.     Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle. 2013 Oct 1; 12(19), 3159-3164.

6.     Hirai H, Iwasawa Y, Okada M, et al. Small-molecule inhibition of Wee-1 kinase by MK-1775 selectively sensitizes p53-edficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009 Nov; 8(11):2992-3000.

7.     Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005 Nov 14;24(50):7455-7464.

8.     Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-644.

9.     Clark AS, West K Streicher S, Dennis PA. Constitutive and inducible AKT activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002 Jul;1(9):707-717.

10.  Huang W-C, Hung M-C. Induction of AKT activity by chemotherapy confers acquired resistance. J Formos Med Assoc. 2009 Mar;108(3):180-194.

11.  Selli, C., et al. Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Res. 2016; 18: 118 .

12.  Basaran GA, et al. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treat Rev. 2018;63:144-155..

13.  Mitri, Z. et al. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2012; 2012: 743193. doi: 10.1155/2012/743193. Accessed April 2019.

14.  Carlson B. HER2 TESTS: How Do We Choose? Biotechnol Healthc. 2008; 5(3): 23–27.

15.  The Royal Marsden NHS Foundation Trust. A beginner’s guide to BRCA1 and BRCA2. Available at: https://www.royalmarsden.nhs.uk/sites/default/files/files_trust/beginners-guide-to-brca1-andbrca2.PDF. Accessed May 2019.


Veeva ID: Z4-17127    
Date of next review: May 2021